omeprazole and Gastritis studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.

Research Excerpts

Excerpt	Relevance	Reference
" pylori-associated gastritis were randomly assigned to one of three arms for a 14-day treatment: Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, or Arm C triple therapy alone."	9.24	Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. ( Fang, JY; Ji, F; Li, JS; Li, YQ; Luo, HQ; Luo, HS; Lv, NH; Qian, JM; Ren, JL; Shi, RH; Tan, B; Xu, H; Zou, YY, 2017)
"To date, guidelines on the impact and value of atropine combined with omeprazole in the treatment of acute gastritis have not been well established or well defined."	9.12	The clinical efficacy and safety of atropine combined with omeprazole in the treatment of patients with acute gastritis: a systematic review and meta-analysis. ( Chen, H; Lin, X; Lin, YN, 2021)
"To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis."	9.12	Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006)
" pylori) gastritis in children by the adjunction of omeprazole (OAC) was studied."	9.12	Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy. ( Alliet, P; Bontemps, P; Cadranel, S; Lauvau, D; Van Biervliet, S; Vandenhoven, G; Vandenplas, Y, 2007)
" This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)."	9.11	Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004)
"Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation."	9.10	Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003)
"Thirty-eight children with Helicobacter pylori gastritis diagnosed by histopathology, and/or bacteriological culture were treated with omeprazole, amoxicillin and clarithromycin."	9.09	Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. ( Finkel, Y; Sandstedt, B; Tirén, U, 1999)
"The aim of this multicenter prospective, randomized, double-blind study was to assess the efficacy of the combination of omeprazole, amoxicillin, and clarithromycin (OAC) for the treatment of Helicobacter pylori gastritis in children."	9.09	Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. ( Barthélemy, P; Dupont, C; Gottrand, F; Guimber, D; Husson, MO; Kalach, N; Lachaux, A; Lenaerts, C; Maurage, C; Morali, A; Mougenot, JF; Roquelaure, B; Spyckerelle, C; Tounian, P, 2001)
"Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo."	9.08	The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995)
"Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers."	9.08	Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, EF, 1996)
" pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H."	9.08	Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996)
"In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0."	9.08	Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997)
" pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day."	9.08	Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998)
" pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day."	9.08	Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998)
"Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis."	9.08	Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998)
"Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease."	9.07	Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994)
"In a controlled, prospective, randomized trial, 10 patients with Helicobacter pylori positive gastritis were treated either with triple therapy (tetracycline, ornidazole, bismuth subcitrate; T, Or, CBS), or omeprazole/CBS (O/CBS) to test the eradication rate of each treatment, its effect on gastritis and meal stimulated gastrin release."	9.07	[Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study]. ( Bertschinger, P; Brunner, J; Flury, R; Häcki, WH; Jost, R; Lammer, F, 1992)
"This study set out to investigate the effects of omeprazole or ranitidine on the progression of antral gastritis and Helicobacter pylori in patients with active duodenal ulcer."	9.07	Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. ( Branicki, FJ; Ho, J; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM, 1991)
"Omeprazole is a mainstay of therapy for gastroesophageal reflux disease (GERD) and gastritis, and is increasingly used as an over-the-counter remedy for dyspepsia."	7.76	Antioxidant pre-treatment prevents omeprazole-induced toxicity in an in vitro model of infectious gastritis. ( Blass, AL; Kohler, JE; Liu, J; Soybel, DI; Tai, K, 2010)
"The present study was designed to investigate the effect of 7,8-dimethoxycoumarin (DMC) isolated from ethyl acetate extract of Citrus decumana peels on gastritis in rats."	7.76	Role of 7,8-dimethoxycoumarin in anti-secretary and anti-inflammatory action on pyloric ligation-induced gastritis in rats. ( Bali, M; Gill, NS; Muthuraman, A; Sharma, PD; Sood, S, 2010)
" This study evaluated the inhibitory action of apigenin-7-O-beta-D-glucuronopyranoside (AGC), apigenin, and omeprazole on reflux oesophagitis and gastritis in rats."	7.73	The effects of apigenin-7-O-beta-D-glucuronopyranoside on reflux oesophagitis and gastritis in rats. ( Bai, KL; Choi, HJ; Ham, I; Jeong, JH; Min, YS; Park, SY; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2005)
"To confirm the immediate-type mechanism of recurrent anaphylactic reactions to the repeated administration of omeprazole using skin testing and to enable safe administration of the drug after successful oral desensitization."	7.73	Anaphylaxis to omeprazole: diagnosis and desensitization protocol. ( Confino-Cohen, R; Goldberg, A, 2006)
"This study evaluated the inhibitory action of luteolin-7-O-beta-D-glucuronopyranoside, luteolin which was isolated from Salix gilgiana leaves, and omeprazole on reflux esophagitis and gastritis in rats."	7.73	The effect of luteolin-7-O-beta-D-glucuronopyranoside on gastritis and esophagitis in rats. ( Bai, KL; Ham, I; Kim, JH; Lee, YJ; Min, YS; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2006)
"Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk."	7.72	Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004)
" pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole."	7.71	Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001)
" We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6."	7.70	Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000)
"An antibiotic combination that includes a proton pump inhibitor such as omeprazole and an antibiotic such as clarithromycin is likely to become the new standard regimen for treatment of Helicobacter pylori gastritis because this combination is extremely effective and very well tolerated."	7.69	Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. ( Getz, HD; Metz, DC, 1995)
"Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy."	7.69	Esophageal candidiasis following omeprazole therapy: a report of two cases. ( Chawla, LS; Jain, NP; Kumar, R; Sharma, M; Sood, A, 1995)
" The patient, who was being treated with digitoxin for heart failure, reported having taken up to four digitoxin tablets (0."	7.69	[Reversible thrombocytopenia due to digitoxin overdose]. ( Kirch, W; Krappweis, J; Petereit, G; Schentke, KU, 1994)
" pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole."	7.69	Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997)
"To evaluate the efficacy of one-week therapy with omeprazole, clarithromycin and amoxycillin in eradicating Helicobacter pylori and healing duodenal ulcer."	7.69	[One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. ( Abraira, V; Alvarez Baleriola, I; Boixeda, D; Ceña, G; García Plaza, A; Gisbert, JP; Martín de Argila, C; Mur, M, 1997)
"A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole."	7.69	Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997)
"Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis."	7.68	Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. ( Brunner, G; Creutzfeldt, W; Lamberts, R; Solcia, E; Strüber, HG, 1993)
"Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o."	7.68	Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. ( Daw, MA; Deegan, P; Leen, E; O'Moráin, C, 1991)
"A double-blind study was conducted to compare gastric ulcer healing time in nontreated dogs with that in dogs treated with either cimetidine or omeprazole."	7.68	Comparison of effects of cimetidine and omeprazole on mechanically created gastric ulceration and on aspirin-induced gastritis in dogs. ( Bright, RM; DeNovo, RC; Jenkins, CC; Patton, CS; Rohrbach, BW, 1991)
" HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)."	6.68	Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995)
"Treatment with omeprazole plus amoxicillin or clarithromycin resulted in encouraging Helicobacter pylori cure rates in pilot and controlled studies."	6.68	High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Domian, C; Labenz, J; Stolte, M, 1995)
" Thus, a true dose-response relationship exists between omeprazole and treatment success."	6.68	Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. ( Beker, JA; Dekker, CP; Farley, A; Jönsson, A; Klör, HU; Labenz, J, 1997)
"Omeprazole was more effective than famotidine in keeping gastric pH high and lowering the total gastric acid output."	5.32	Omeprazole is more effective than famotidine for preventing acute gastritis in rats. ( Akturk, Z; Ekinci, H; Muftuoglu, T; Peker, O; Topaloglu, U; Unalmiser, S, 2004)
"Lymphocytic gastritis is characterized by intense lymphocytic infiltration of gastric epithelium."	5.31	[Edematous syndrome revealing an exudative lymphocytic gastritis: efficacy of omeprazole]. ( Bellanger, J; Cacoub, P; Costedoat-Chalumeau, N; Godeau, P; Piette, JC; Sbaï, A, 2000)
"It is used for treatment of gastroduodenal ulcers, reflux oesophagitis and Zollinger Ellison's syndrome."	5.29	[The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis]. ( Drábek, J; Hanika, J; Soucková, A; Vejvalka, J; Zelenková, J; Zeman, V, 1993)
"Treatment with omeprazole, a proton pump inhibitor, for 2 months, followed by famotidine, resulted in clinical improvement with resolution of the gastroduodenal lesions and protein loss."	5.29	Varioliform gastritis and duodenitis associated with protein-losing gastroenteropathy, treated with omeprazole. ( Kuroda, T; Miura, T; Murata, I; Otsuki, M; Tabaru, A; Yoshikawa, I, 1996)
"Omeprazole treatment produces lower intragastric pH values 4 weeks after cure of Helicobacter pylori infection than before."	5.29	Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. ( Armstrong, D; Blum, AL; Börsch, G; Idström, JP; Labenz, J; Stolte, M; Verdú, EF, 1996)
"Treatment with omeprazole also failed to bring about healing of the ulceration which, at times, measured up to 10 cm in diameter."	5.28	Failure of ranitidine and omeprazole treatment in eosinophilic gastritis with ulceration. ( Gail, K; Mihaljevic, L; Stolte, M, 1991)
" pylori-associated gastritis were randomly assigned to one of three arms for a 14-day treatment: Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, or Arm C triple therapy alone."	5.24	Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. ( Fang, JY; Ji, F; Li, JS; Li, YQ; Luo, HQ; Luo, HS; Lv, NH; Qian, JM; Ren, JL; Shi, RH; Tan, B; Xu, H; Zou, YY, 2017)
" pylori-related chronic gastritis who were randomly provided either 10-day omeprazole-based triple therapy (OM-triple; omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily) or 10-day B-quadruple therapy (OM-triple + bismuth subcitrate 120 mg four times daily)."	5.24	Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. ( Chen, C; Chen, S; Ding, J; Du, Q; Huang, Z; Jiang, Y; Li, J; Li, W; Lin, Z; Meng, L; Si, J; Wang, L; Wu, L; Ye, B, 2017)
" pylori infection was statistically significantly dependent on omeprazole dosage, CYP2C19 genotype, age, gastritis status, and H."	5.15	Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. ( Chern, HD; Lin, BR; Lin, CJ; Shun, CT; Wang, HL; Wang, TH; Yang, JC, 2011)
"Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo."	5.12	Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. ( Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC, 2006)
" Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83."	5.12	Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. ( Bayerdörffer, E; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Neuber, F; Rappel, S; Seitz, G; Stolte, M, 2006)
"To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis."	5.12	Furazolidone-based triple therapy for H pylori gastritis in children. ( Bonucci, VC; Carelli, AP; Fukushima, E; Kawakami, E; Langner, M; Machado, RS; Ogata, SK; Patricio, FR, 2006)
" pylori) gastritis in children by the adjunction of omeprazole (OAC) was studied."	5.12	Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy. ( Alliet, P; Bontemps, P; Cadranel, S; Lauvau, D; Van Biervliet, S; Vandenhoven, G; Vandenplas, Y, 2007)
" This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD)."	5.11	Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. ( Dent, J; Festen, HP; Goldfain, D; Havu, N; Klinkenberg-Knol, EC; Kolkman, JJ; Kuipers, EJ; Lamm, M; Nelis, GF; Snel, P; Walan, A; Zeitoun, P, 2004)
"Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period."	5.11	Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005)
" pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks)."	5.10	[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. ( Cui, M; Hu, F; Jiang, H; Zheng, X, 2002)
" pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week."	5.10	Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003)
"Both sucralfate and rabeprazole therapies are effective treatment options in the patients with alkaline gastritis when compared with observation."	5.10	Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. ( Cammarota, G; Candelli, M; Cremonini, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Nista, EC; Santarelli, L, 2003)
"Thirty-eight children with Helicobacter pylori gastritis diagnosed by histopathology, and/or bacteriological culture were treated with omeprazole, amoxicillin and clarithromycin."	5.09	Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. ( Finkel, Y; Sandstedt, B; Tirén, U, 1999)
" All patients belong to a low socioeconomic strata, had multifocal atrophic gastritis documented by gastric biopsies, and had been treated previously and unsuccessfully for 2 weeks with bismuth subsalicylate (262 mg four times a day), amoxicillin (500 mg three times a day), and metronidazole (400 mg three times a day)."	5.09	Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. ( Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL, 1999)
" pylori-infected patients with nonulcer dyspepsia to receive twice-daily treatment with 20 mg of omeprazole, 1000 mg of amoxicillin, and 500 mg of clarithromycin for 14 days and 167 such patients to receive identical-appearing placebos; all patients were then followed through regular visits for 12 months."	5.09	Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. ( Ballard, ED; Fennerty, MB; Talley, NJ; Vakil, N, 1999)
" pylori-positive patients who had peptic ulcers or reflux oesophagitis were treated for 3 years with either omeprazole (20 mg/day) alone (n=7) or with omeprazole for primary therapy (8 weeks), followed by famotidine (40 mg/day) for maintenance therapy (n=134)."	5.09	Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. ( Mashiba, H; Matsumura, N; Okamoto, S; Sasaki, N; Taniyama, K; Uemura, N; Yamaguchi, S; Yamamoto, S, 2000)
"Among the 15 patients with hemorrhagic acute gastritis who were randomly allocated to group A (eradication therapy) or group B (Lansoprazole, LPZ), 10 of them started to receive treatment within 1 day after the disease onset."	5.09	A short-term eradication therapy for Helicobacter pylori acute gastritis. ( Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T, 2000)
"The aim of this multicenter prospective, randomized, double-blind study was to assess the efficacy of the combination of omeprazole, amoxicillin, and clarithromycin (OAC) for the treatment of Helicobacter pylori gastritis in children."	5.09	Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. ( Barthélemy, P; Dupont, C; Gottrand, F; Guimber, D; Husson, MO; Kalach, N; Lachaux, A; Lenaerts, C; Maurage, C; Morali, A; Mougenot, JF; Roquelaure, B; Spyckerelle, C; Tounian, P, 2001)
"A total of 170 Helicobacter pylori-positive patients with chronic gastritis were randomized to receive one of the following Helicobacter pylori eradication regimens; OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week) and RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)."	5.09	Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. ( Azuma, T; Dojo, M; Kuriyama, M; Muramatsu, A; Ohtani, M; Saito, T, 2001)
" Men between 55 and 65 years of age with a gastric cancer phenotype of Helicobacter pylori gastritis are randomized to receive a 7 day course of omeprazole 2 X 20mg, clarithromycin 2 X 500mg, and amoxicillin 2 X 1g for 7 days, or omeprazole 2 X 20mg plus placebo."	5.09	Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). ( Antos, D; Bayerdörffer, E; Dite, P; Dragosics, B; Ehninger, G; Gschwantler, M; Kirsch, C; Labenz, J; Läuter, J; Leodolter, A; Malfertheiner, P; Miehlke, S; Neubauer, A; Oberhuber, G; Stolte, M, 2001)
"Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo."	5.08	The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995)
"pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd."	5.08	[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995)
"Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers."	5.08	Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. ( Blum, AL; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B; Verdú, EF, 1996)
"The combined therapy with amoxycillin, metronidazole, and omeprazole is highly effective in both HP eradication and prevention of duodenal ulcer recurrence."	5.08	Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. ( Alvisi, C; Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Luinetti, O; Maconi, G; Perego, M; Solcia, E; Trespi, E; Villani, L, 1996)
"Changes in Helicobacter pylori-associated gastritis of the antrum and corpus were investigated in a large number of patients treated with omeprazole, with or without the addition of amoxycillin."	5.08	Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. ( Carlsson, J; Fiocca, R; Rudbäck, A; Solcia, E; Villani, L; Zeijlon, L, 1996)
" pylori infection in patients with chronic gastritis (CG), duodenal ulcer (DU), and gastric ulcer (GU) after two dual therapies (omeprazole with either amoxycillin or clarithromycin)."	5.08	Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. ( Carpintero, P; García Grávalos, R; Hermida, C; Lara, S; Moreno, JA; Pajares, JM; Santander, C, 1996)
" pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients."	5.08	Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997)
" pylori-associated gastritis were treated with 20 mg omeprazole once daily in the morning, 20 mg omeprazole b."	5.08	An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. ( Bayerdörffer, E; Hele, C; Lehn, N; Mannes, GA; Miehlke, S; Stolte, M, 1997)
"The purpose of the present study was to examine the association between interleukin-8 (IL-8) in the gastric body due to Helicobacter pylori infection and histological gastritis, as well as elucidating the effect of acid secretion inhibitors on H."	5.08	Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. ( Haruma, K; Kajiyama, G; Mashiba, H; Mukai, T; Okamoto, S; Oomoto, Y; Sasaki, N; Sumii, K; Taniyama, K; Uemura, N; Yamaguchi, S, 1997)
" pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone."	5.08	Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996)
" pylori from the gastric mucosa, and omeprazole frequently is used for the treatment of duodenal ulcer disease, prompting the interest to investigate rigorously the combination of clarithromycin and omeprazole for eradicating H."	5.08	Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. ( Dettmer, A; Fraser, AG; O'Morain, C; Rambow, A; von Fritsch, E, 1996)
" Patients (n = 787) with proved duodenal ulcer disease were randomized to treatment twice daily for 1 week with omeprazole, 20 mg (O), plus either placebo (P) or combinations of two of the following antimicrobials: amoxicillin, 1 gm (A), clarithromycin, 250 or 500 mg (C250, C500), or metronidazole, 400 mg (M)."	5.08	Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. ( Bardhan, KD; Bayerdörffer, E; Bradette, M; Cederberg, C; Chiba, N; Idström, JP; Lind, T; O'Morain, C; Spiller, R; Unge, P; Veldhuyzen van Zanten, S; Wrangstadh, M, 1996)
"In this randomized multicentre study, 267 duodenal ulcer patients were treated for 2 weeks with omeprazole 40 bid (Group A) or 20 mg bid (Group B), respectively, and with amoxycillin 0."	5.08	Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. ( Annibale, B; Bordi, C; Cesana, B; Damilano, I; Franceschi, M; Maconi, G; Pilato, FP, 1997)
" pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day."	5.08	Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998)
" pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day."	5.08	Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998)
" pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment."	5.08	Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998)
"Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis."	5.08	Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998)
"Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease."	5.07	Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994)
" pylori infection and gastritis were treated with one of the following four regimens: omeprazole 40 mg/day for one week (group A, n = 14); omeprazole 40 mg/day for one week followed by clarithromycin 1 g/day for 2 weeks (group B, n = 26); omeprazole 40 mg/day for one week followed by tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day, both for two weeks (group C, n = 26); and tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group D, n = 22)."	5.07	Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. ( Cuccurullo, F; Di Iorio, P; Laterza, F; Mezzetti, A; Neri, M; Seccia, G; Susi, D, 1994)
"In a controlled, prospective, randomized trial, 10 patients with Helicobacter pylori positive gastritis were treated either with triple therapy (tetracycline, ornidazole, bismuth subcitrate; T, Or, CBS), or omeprazole/CBS (O/CBS) to test the eradication rate of each treatment, its effect on gastritis and meal stimulated gastrin release."	5.07	[Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study]. ( Bertschinger, P; Brunner, J; Flury, R; Häcki, WH; Jost, R; Lammer, F, 1992)
"In an open study, 62 patients with Helicobacter pylori-associated ulcer disease or functional dyspepsia were treated for two weeks with 2 x 20 mg omeprazole preprandially and 4 x 500 mg amoxicillin suspension one hour before meals and at night."	5.07	Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1992)
" pylori-associated gastritis were allocated to one of the following four therapeutic schedules: 1) omeprazole 40 mg/d for 4 weeks (n = 13); 2) bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12); 3) omeprazole plus BSS for 4 weeks (n = 13); 4) triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)."	5.07	The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. ( Bär, W; Gebel, M; Haruma, K; Lange, P; Müller, MJ; Schorn, T; Soudah, B; Varrentrapp, M; Wagner, S, 1991)
"This study set out to investigate the effects of omeprazole or ranitidine on the progression of antral gastritis and Helicobacter pylori in patients with active duodenal ulcer."	5.07	Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. ( Branicki, FJ; Ho, J; Hui, WM; Lai, CL; Lam, SK; Lau, WY; Lok, AS; Ng, MM, 1991)
" In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole."	4.78	Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993)
" pylori culture positive dyspeptic patients (64 patients with peptic ulcer, PU) completed a 2-week treatment with omeprazole, amoxicillin and metronidazole and underwent endoscopy again 6-8 weeks after the end of therapy."	3.78	Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection. ( Figura, N; Giordano, N; Langone, F; Moretti, E; Vaglio, L; Vernillo, R; Vindigni, C, 2012)
"Omeprazole is a mainstay of therapy for gastroesophageal reflux disease (GERD) and gastritis, and is increasingly used as an over-the-counter remedy for dyspepsia."	3.76	Antioxidant pre-treatment prevents omeprazole-induced toxicity in an in vitro model of infectious gastritis. ( Blass, AL; Kohler, JE; Liu, J; Soybel, DI; Tai, K, 2010)
"The present study was designed to investigate the effect of 7,8-dimethoxycoumarin (DMC) isolated from ethyl acetate extract of Citrus decumana peels on gastritis in rats."	3.76	Role of 7,8-dimethoxycoumarin in anti-secretary and anti-inflammatory action on pyloric ligation-induced gastritis in rats. ( Bali, M; Gill, NS; Muthuraman, A; Sharma, PD; Sood, S, 2010)
"The authors made an attempt to find a new approach to Helicobacter pylori (HP) eradication in patients with chronic gastritis and peptic ulcer without application of antibiotics, but using melatonin properties instead."	3.74	[Antihelicobacter effects of melatonin]. ( Malinovskaia, NK; Parkhomenko, IE; Postnikova, LI; Rapoport, SI; Rybnikova, SN; Zhernakova, NI, 2007)
"This is our final report on the clinical effectiveness and safety of long-term pantoprazole in patients with severe peptic ulcer or reflux disease during continuous treatment for up to 5 years."	3.73	Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. ( Bardhan, KD; Bishop, AE; Luehmann, R; McCaldin, B; Morris, P; Polak, JM; Romanska, HM; Rowland, A; Schaefer-Preuss, S; Thompson, M, 2005)
" This study evaluated the inhibitory action of apigenin-7-O-beta-D-glucuronopyranoside (AGC), apigenin, and omeprazole on reflux oesophagitis and gastritis in rats."	3.73	The effects of apigenin-7-O-beta-D-glucuronopyranoside on reflux oesophagitis and gastritis in rats. ( Bai, KL; Choi, HJ; Ham, I; Jeong, JH; Min, YS; Park, SY; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2005)
" The patient was also treated with omeprazole (20 mg/day) because of chronic gastritis."	3.73	Gastric pH, sevelamer hydrochloride and omeprazole. ( Capitanini, A; Del Corso, C; Gallieni, M; Lupi, A; Osteri, F; Petrone, I; Rossi, A; Straniti, M, 2005)
"To confirm the immediate-type mechanism of recurrent anaphylactic reactions to the repeated administration of omeprazole using skin testing and to enable safe administration of the drug after successful oral desensitization."	3.73	Anaphylaxis to omeprazole: diagnosis and desensitization protocol. ( Confino-Cohen, R; Goldberg, A, 2006)
"This study evaluated the inhibitory action of luteolin-7-O-beta-D-glucuronopyranoside, luteolin which was isolated from Salix gilgiana leaves, and omeprazole on reflux esophagitis and gastritis in rats."	3.73	The effect of luteolin-7-O-beta-D-glucuronopyranoside on gastritis and esophagitis in rats. ( Bai, KL; Ham, I; Kim, JH; Lee, YJ; Min, YS; Sohn, UD; Song, HJ; Whang, WK; Yim, SH, 2006)
" pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid."	3.72	Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003)
"Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk."	3.72	Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004)
" The patient underwent 7 days of clarithromycin, amoxicillin, and omeprazole treatment for Helicobacter pylori-associated gastritis."	3.72	Acute colchicine intoxication during clarithromycin administration. ( Blanche, P; Chauvelot-Moachon, L; Kélaïdi, C; Nazal, EM; Pajot, O; Rollot, F, 2004)
" pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole."	3.71	Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001)
" Therefore, we investigated how the chronic gastritis in mice made hypochlorhydric by either gastrin deficiency or omeprazole treatment modulates epithelial cell function."	3.71	Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. ( Ferguson, A; Merchant, JL; Rieder, G; Samuelson, LC; Zavros, Y, 2002)
"Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed."	3.70	Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. ( Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M, 1998)
"Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H."	3.70	Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998)
" pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o."	3.70	Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998)
"One hundred eight patients with cultured H pylori-positive gastritis or peptic ulcer were treated with three regimens: quadruple treatment without proton pump inhibitors (n = 25), dual treatment with omeprazole and amoxicillin (INN, amoxicilline) (n = 26), and triple treatment with omeprazole, amoxicillin, and clarithromycin (n = 57)."	3.70	CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. ( Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y, 1999)
" pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk."	3.70	The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000)
" We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6."	3.70	Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000)
" Given the histology and the fact that rapid urease test results were positive, chronic active gastritis with H."	3.70	Iron-deficiency anemia associated with Helicobacter pylori gastritis. ( Imai, T; Konno, M; Muraoka, S; Takahashi, M, 2000)
" pylori lipopolysaccharide-induced acute gastritis to study the effect of antiulcer agents, omeprazole and sucralfate, on the course of mucosal inflammatory responses by analyzing the interplay between the extent of epithelial cell apoptosis and the mucosal expression of endothelin-1 (ET-1), tumor necrosis factor-alpha (TNF-alpha), and the activity of constitutive (cNOS) and inducible (NOS-2) nitric oxide synthase."	3.70	Up-regulation of endothelin-1 in gastric mucosal inflammatory responses to Helicobacter pylori Lipopolysaccharide: effect of omeprazole and sucralfate. ( Piotrowski, J; Slomiany, A; Slomiany, BL, 2000)
" pylori with omeprazole and amoxicillin, the skin changes, gastric complaints, and proteinuria disappeared."	3.69	Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. ( Borchard, F; Goerz, G; Megahed, M; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1995)
" pylori testing in patients on profound acid suppressive therapy should be performed on combined corpus and antral specimens, and 2) that omeprazole therapy leads to a strong increase in corpus gastritis, which may explain the observed development of corpus atrophy in a substantial number of patients after several years of continuous acid suppressive treatment."	3.69	Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. ( Bloemena, E; Hazenberg, HJ; Klinkenberg-Knol, EC; Kuipers, EJ; Lindeman, J; Meuwissen, SG; Peña, AS; Uyterlinde, AM, 1995)
"An antibiotic combination that includes a proton pump inhibitor such as omeprazole and an antibiotic such as clarithromycin is likely to become the new standard regimen for treatment of Helicobacter pylori gastritis because this combination is extremely effective and very well tolerated."	3.69	Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. ( Getz, HD; Metz, DC, 1995)
" 33 patients with primary gastric low-grade MALT lymphoma associated with H pylori gastritis were treated with omeprazole (120 mg daily) and amoxycillin (2."	3.69	Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. ( Bayerdörffer, E; Eidt, S; Lehn, N; Neubauer, A; Rudolph, B; Stolte, M; Thiede, C, 1995)
"Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy."	3.69	Esophageal candidiasis following omeprazole therapy: a report of two cases. ( Chawla, LS; Jain, NP; Kumar, R; Sharma, M; Sood, A, 1995)
"These findings indicate that (1) peptic esophagitis was a common cause of chronic abdominal pain in pediatric patients and (2) omeprazole was effective in the treatment of esophagitis in children and adolescents that was resistant to high-dose histamine2-receptor antagonists."	3.69	Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. ( Kane, R; Karjoo, M, 1995)
" The patient, who was being treated with digitoxin for heart failure, reported having taken up to four digitoxin tablets (0."	3.69	[Reversible thrombocytopenia due to digitoxin overdose]. ( Kirch, W; Krappweis, J; Petereit, G; Schentke, KU, 1994)
"Bacterial overgrowth of the small intestine commonly occurs in association with hypochlorhydria caused by atrophic gastritis or during treatment with omeprazole."	3.69	Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. ( Golner, B; Kowdley, KV; Pedrosa, MC; Perrone, G; Russell, RM; Saltzman, JR; Sepe, T, 1994)
" pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole."	3.69	Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997)
"To evaluate the efficacy of one-week therapy with omeprazole, clarithromycin and amoxycillin in eradicating Helicobacter pylori and healing duodenal ulcer."	3.69	[One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. ( Abraira, V; Alvarez Baleriola, I; Boixeda, D; Ceña, G; García Plaza, A; Gisbert, JP; Martín de Argila, C; Mur, M, 1997)
"A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole."	3.69	Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997)
" Thirty-two consecutive patients (suffering from either peptic ulcer or nonulcer dyspepsia) with Helicobacter pylori infection received omeprazole (40 mg) + bismuth subcitrate (240 mg x 4) + amoxicillin suspension (2000 mg x 4) + metronidazole (500 mg x 4), for only one day."	3.68	One-day therapy for treatment of Helicobacter pylori infection. ( Barbara, L; Biasco, G; Corinaldesi, R; Gasperoni, S; Paparo, GF; Ricci-Maccarini, M; Stanghellini, V; Tucci, A; Varoli, O, 1993)
"Long-term omeprazole therapy in humans results in moderate hypergastrinemia and a significant argyrophil cell hyperplasia, which are correlated to the grade of corpus gastritis."	3.68	Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. ( Brunner, G; Creutzfeldt, W; Lamberts, R; Solcia, E; Strüber, HG, 1993)
"Twenty-one patients with endoscopically confirmed duodenal ulceration, who had failed to heal with an H2-antagonist, were given omeprazole 20 mg o."	3.68	Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. ( Daw, MA; Deegan, P; Leen, E; O'Moráin, C, 1991)
"A double-blind study was conducted to compare gastric ulcer healing time in nontreated dogs with that in dogs treated with either cimetidine or omeprazole."	3.68	Comparison of effects of cimetidine and omeprazole on mechanically created gastric ulceration and on aspirin-induced gastritis in dogs. ( Bright, RM; DeNovo, RC; Jenkins, CC; Patton, CS; Rohrbach, BW, 1991)
"Biopsies from the stomachs (antrum and corpus) of 201 patients with peptic ulcers or reflux oesophagitis were retrospectively investigated for the effect of treatment with omeprazole on the elimination of Helicobacter pylori (HP) and on gastritis."	3.68	Elimination of Helicobacter pylori under treatment with omeprazole. ( Bethke, B; Stolte, M, 1990)
"Gastritis was assessed according to the updated Sydney classification for activity, chronic inflammation, gastric glandular atrophy, intestinal metaplasia, and H."	2.74	Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. ( Bijlsma, JW; Bloemena, E; Boers, M; De Leest, HT; Dijkmans, BA; Houben, HH; Janssen, M; Kostense, PJ; Kuipers, EJ; Lems, WF; Steen, KS; Van de Laar, MA, 2009)
"pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers."	2.71	Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. ( Figueroa, LS; Guarner, J; Halperin, D; Herrera-Goepfert, R; Johnstone, I; Ley, C; Mohar, A; Parsonnet, J, 2004)
"Esomeprazole has higher oral bioavailability and increased antimicrobial activity against Helicobacter pylori than omeprazole."	2.71	Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. ( Anagnostopoulos, GK; Arvanitidis, D; Kostopoulos, P; Margantinis, G; Tsiakos, S, 2004)
" A therapeutical scheme (omeprazole, metronidazole, amoxicilline) obtained a further pathogenetic substantiation of B type CG patient treatment with additional antioxidant vitamin E use at the dosage of 300 mg/day for three weeks."	2.71	[Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis]. ( Postavnyĭ, VE, 2005)
"Helicobacter pylori gastritis is usually a lifelong disease which can cause different topographical inflammatory reactions and induce divergent effects on acid secretion in humans."	2.70	Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia. ( Färkkilä, M; Koskenpato, J; Sipponen, P, 2002)
" We performed serial endoscopy, checked for adverse events, and laboratory values."	2.70	Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. ( Bardhan, KD; Bishop, AE; Cherian, P; Fischer, R; Lühmann, R; McCaldin, B; Morris, P; Ng, W; Perry, MJ; Polak, JM; Romanska, H; Rowland, A; Schneider, A; Thompson, M, 2001)
" Sixty-eight patients received 30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks (LAM group), while the other 67 patients received the same dosage of those agents plus 18,000 tyrosine units of pronase thrice daily for 2 weeks (LAMP group)."	2.70	Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. ( Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A, 2002)
"Omeprazole pretreatment did not influence eradication rates."	2.69	Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study. ( Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD; Victor, L, 1998)
"The 1-week triple therapy was safe and effective for eradicating H."	2.69	Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. ( Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T, 1998)
"pylori-related gastritis, have focused mainly on medium and long-term change following eradication therapies."	2.69	Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. ( Chadwick, VS; Chen, W; Shu, D; Tie, A; Wilson, IR, 1999)
"Chronic urticaria is one of the most frequent skin diseases."	2.69	Helicobacter pylori as a possible bacterial focus of chronic urticaria. ( Brehler, R; Domschke, W; Foerster, E; Luger, TA; Pohle, T; Wustlich, S, 1999)
" The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)."	2.69	Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999)
"Metronidazole resistance was found in 44% of pre-treatment cultures of H."	2.69	Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. ( Axon, AT; Bardhan, KD; Braun, W; Cooper, BT; Dillon, J; Gatz, G; Tildesley, G; Wyatt, JI, 2000)
"We present data on development of GERD from a controlled study of H."	2.69	Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. ( Befrits, R; Lindberg, G; Odman, B; Sjöstedt, S; Sörngård, H, 2000)
"pylori-positive GERD patients randomly assigned to either an eradication or omeprazole-alone regime."	2.69	Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. ( Axon, AT; Bardhan, K; Dixon, MF; Moayyedi, P; Peacock, R; Walan, A; Wason, C, 2000)
" HP was eradicated by combined treatment with high-dose omeprazole (2 x 40 mg) and amoxicillin (2 x 1,000 mg; n = 27) administered for 10 days (OME + AMX); alternatively, patients were treated with omeprazole monotherapy (OME) using the same dosage (n = 25)."	2.68	Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. ( Bayerdörffer, E; Dirschedl, P; Hatz, R; Höchter, W; Lehn, N; Mannes, GA; Miehlke, S; Ruckdeschel, G; Sommer, A; Weingart, J, 1995)
"Treatment with omeprazole plus amoxicillin or clarithromycin resulted in encouraging Helicobacter pylori cure rates in pilot and controlled studies."	2.68	High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. ( Bertrams, J; Börsch, G; Domian, C; Labenz, J; Stolte, M, 1995)
"Omeprazole has a strong inhibitory effect on H."	2.68	Effect of omeprazole on Helicobacter pylori urease activity in vivo. ( Domínguez-Muñoz, JE; Kalhori, N; Malfertheiner, P; Sauerbruch, T; Stoschus, B, 1996)
"In five of 20 patients, MALT lymphomas were finally diagnosed."	2.68	Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? ( Bayerdörffer, E; Hatz, R; Lehn, N; Müller, S; Neubauer, A; Neubauer, B; Otto, P; Ritter, M; Rudolph, B; Seifert, E; Stolte, M; Thiede, C, 1997)
" Thus, a true dose-response relationship exists between omeprazole and treatment success."	2.68	Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. ( Beker, JA; Dekker, CP; Farley, A; Jönsson, A; Klör, HU; Labenz, J, 1997)
" Group II (n = 47) treated with the same drug and dosage for 2 weeks."	2.68	[Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. ( Bei, L; Chen, S; Chen, Z, 1996)
" Physiologic factors that may contribute to a poor response to these drugs include the considerable variation in the bioavailability of PPIs, the need to take PPIs with meals, the influence of Helicobacter pylori-associated gastritis, and genetic variation in enzyme capacity, resulting in rapid and slow metabolizers of PPIs."	2.42	Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease. ( Richter, JE, 2003)
" Conversely, several studies have shown that long-term use of proton pump inhibitors is associated with progression and worsening of body gastritis exclusively in Helicobacter pylori-positives."	2.40	Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors? ( Rauws, EA, 1997)
"argyrophilic gastric carcinoids."	2.38	Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis. ( Rindi, G; Silini, E; Solcia, E; Villani, L, 1993)
"Gastritis is a common inflammation of stomach with multiple pathogenesis."	1.72	Octreotide-based therapies effectively protect mice from acute and chronic gastritis. ( Cao, LJ; Cao, WL; Che, Y; Ding, CJ; Huang, H; Wang, Y; Wu, JW; Xu, WF; Zhang, Q, 2022)
" Examination of eradication rates according to CAM dosage revealed an eradication rate of 65."	1.40	Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014)
"In two patients with MALT lymphoma, H."	1.33	Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. ( Akamatsu, T; Hidaka, E; Matsuzawa, K; Okiyama, Y; Ota, H; Sano, K, 2005)
"Chronic gastritis was evaluated according to sydney system."	1.33	[Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori]. ( Ben Ayed, M; Ben Khelifa, H; Chedly-Debbiche, A; Gargouri, D; Ghorbel, AJ; Kharrat, J; Khayat, O; Kilani, A; Souissi, A; Zeddini, A, 2006)
"Omeprazole, 20 mg b."	1.32	Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. ( el-Zimaity, HM; Graham, DY; Opekun, AR; Osato, MS; Yamaoka, Y, 2003)
"Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium."	1.32	Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003)
"We report on two patients with schizoaffective disorder who received omeprazole in addition to clozapine because of gastrointestinal complaints."	1.32	Omeprazole reduces clozapine plasma concentrations. A case report. ( Bergemann, N; Frick, A; Kopitz, J, 2003)
"Omeprazole was more effective than famotidine in keeping gastric pH high and lowering the total gastric acid output."	1.32	Omeprazole is more effective than famotidine for preventing acute gastritis in rats. ( Akturk, Z; Ekinci, H; Muftuoglu, T; Peker, O; Topaloglu, U; Unalmiser, S, 2004)
" pylori-infected mucosa and that inhibited the loss of CAM bioavailability in the acidic environment."	1.32	Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. ( Fujioka, T; Kashimura, K; Kodama, M; Miura, M; Miyajima, H; Murakami, K; Nasu, M; Okimoto, T; Ootsu, S; Sato, R; Watanabe, K, 2004)
"Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors."	1.31	Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002)
"pylori and oesophagitis is mediated by the effect of H."	1.31	Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? ( Bianchi Porro, G; Pace, F, 2000)
"Treatment with omeprazole, amoxicillin, and clarithromycin resulted in eradication of the infection in all and in resolution of the clinical symptoms in 15 (80%) of 19 patients who had a follow-up examination."	1.31	Helicobacter pylori infection in recurrent abdominal pain. ( Braegger, CP; Frank, F; Stallmach, T; Stricker, T, 2000)
"Lymphocytic gastritis is characterized by intense lymphocytic infiltration of gastric epithelium."	1.31	[Edematous syndrome revealing an exudative lymphocytic gastritis: efficacy of omeprazole]. ( Bellanger, J; Cacoub, P; Costedoat-Chalumeau, N; Godeau, P; Piette, JC; Sbaï, A, 2000)
"When omeprazole-treated mice were treated with antibiotics alone, elevated plasma gastrin levels returned to baseline and D cell numbers returned to resting levels despite persistent hypochlorhydria."	1.31	Hypergastrinemia in response to gastric inflammation suppresses somatostatin. ( Ferguson, A; Merchant, JL; Rieder, G; Samuelson, LC; Zavros, Y, 2002)
"Chronic gastritis was diagnosed in 63 (77."	1.31	Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis. ( Ateşkan, U; Mas, MR; Ozdemir, A; Sağlamkaya, U; Sahin, S, 2001)
"Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions."	1.30	Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997)
"More than 90% of gastric MALT lymphomas are diagnosed in patients with chronic, Helicobacter pylori-associated gastritis."	1.30	Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. ( Alpen, B; Bayerdörffer, E; Ehninger, G; Morgner, A; Neubauer, A; Neubauer, B; Ritter, M; Stolte, M; Thiede, C; Wündisch, T, 1997)
"Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55."	1.30	A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997)
"Gastritis was scored according to Sydney criteria."	1.30	Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy. ( Angelucci, D; Cellini, L; Di Campli, E; Diodoro, MG; Grossi, L; Marzio, L, 1998)
"The laryngitis was clinically and endoscopically unchanged in ten of the twelve (83."	1.30	[Is chronic laryngitis associated with Helicobacter pylori? Results of a prospective study]. ( Arps, H; Diehl, KL; Draf, W; Jaspersen, D; Kind, M; Weber, R, 1998)
"Pretreatment with omeprazole (30 mg/kg s."	1.30	Influence of rebamipide on indometacin-induced gastric hemorrhage in rats under restraint stress. ( Arakawa, T; Higuchi, K; Kobayashi, K; Kuroki, T; Takaishi, O; Yamasaki, K, 1999)
"H."	1.29	Prevalence of Helicobacter pylori infection in patients with large gastric folds: evaluation and follow-up with endoscopic ultrasound before and after antimicrobial therapy. ( Avunduk, C; Coughlin, B; Hampf, F; Navab, F, 1995)
"It is used for treatment of gastroduodenal ulcers, reflux oesophagitis and Zollinger Ellison's syndrome."	1.29	[The effect of omeprazole on healing of duodenal ulcers, Helicobacter pylori and gastritis]. ( Drábek, J; Hanika, J; Soucková, A; Vejvalka, J; Zelenková, J; Zeman, V, 1993)
"Treatment with omeprazole, a proton pump inhibitor, for 2 months, followed by famotidine, resulted in clinical improvement with resolution of the gastroduodenal lesions and protein loss."	1.29	Varioliform gastritis and duodenitis associated with protein-losing gastroenteropathy, treated with omeprazole. ( Kuroda, T; Miura, T; Murata, I; Otsuki, M; Tabaru, A; Yoshikawa, I, 1996)
"Omeprazole treatment produces lower intragastric pH values 4 weeks after cure of Helicobacter pylori infection than before."	1.29	Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. ( Armstrong, D; Blum, AL; Börsch, G; Idström, JP; Labenz, J; Stolte, M; Verdú, EF, 1996)
"Treatment with omeprazole also failed to bring about healing of the ulceration which, at times, measured up to 10 cm in diameter."	1.28	Failure of ranitidine and omeprazole treatment in eosinophilic gastritis with ulceration. ( Gail, K; Mihaljevic, L; Stolte, M, 1991)
"The omeprazole plasma levels were 611 +/- 323 and 881 +/- 533 ng/ml after 2 and 4 h."	1.28	Effect of omeprazole on nocturnal intragastric pH in cirrhotics with inadequate antisecretory response to ranitidine. ( Bode, JC; Klotz, U; Sarem-Aslani, A; Treiber, G; Walker, S, 1991)
"2."	1.28	[Current perspectives in ulcer disease]. ( Beglinger, C, 1990)

Research

Studies (388)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Number of Participants in Which H. Pylori Was Eradicated

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (1.03)	18.7374
1990's	190 (48.97)	18.2507
2000's	161 (41.49)	29.6817
2010's	28 (7.22)	24.3611
2020's	5 (1.29)	2.80

Authors	Studies
Lin, X	1
Chen, H	1
Lin, YN	1
Xu, WF	1
Wang, Y	1
Huang, H	1
Wu, JW	1
Che, Y	1
Ding, CJ	1
Zhang, Q	1
Cao, WL	1
Cao, LJ	1
Kim, SE	1
Memon, A	1
Kim, BY	1
Jeon, H	1
Lee, WK	1
Kang, SC	1
Yu, L	1
Li, R	1
Liu, W	2
Zhou, Y	1
Li, Y	1
Qin, Y	1
Chen, Y	1
Xu, Y	1
Santos Santamarta, F	1
Bonoso Criado, R	1
Pérez-Millán, AG	1
Tan, B	1
Luo, HQ	1
Xu, H	1
Lv, NH	1
Shi, RH	1
Luo, HS	1
Li, JS	1
Ren, JL	1
Zou, YY	1
Li, YQ	1
Ji, F	1
Fang, JY	1
Qian, JM	1
Qin, S	1
Huang, K	1
Fang, Z	1
Yin, J	1
Dai, R	1
Agudo-Fernández, S	1
González Blanco, A	1
Salar, A	1
Köksal, AS	1
Onder, FO	1
Torun, S	1
Parlak, E	1
Sayilir, A	1
Tayfur, O	1
Yildiz, H	1
Ozbalci, GS	1
Kayaçetin, E	1
Sarkeshikian, SS	1
Iranikhah, A	1
Ghadir, MR	1
Baracho, NC	1
Ribeiro, RV	1
Pereira, RM	1
Irulegui, Rde S	1
Lambert, D	1
Rouger, C	1
Diebold, MD	1
Ramaholimihaso, F	1
Boulagnon, C	1
Nguyen, Y	1
Hentzien, M	1
Jaussaud, R	1
Bani-Sadr, F	1
Poirier-Guay, MP	1
Bélanger, MC	1
Frank, D	1
Kawai, T	1
Takahashi, S	2
Suzuki, H	4
Sasaki, H	1
Nagahara, A	1
Asaoka, D	1
Matsuhisa, T	1
Masaoaka, T	1
Nishizawa, T	1
Suzuki, M	3
Ito, M	2
Kurihara, N	1
Omata, F	1
Mizuno, S	1
Torii, A	1
Kawakami, K	1
Ohkusa, T	1
Tokunaga, K	1
Mine, T	1
Sakaki, N	1
Batgi, H	1
Akbal, E	1
Koçak, E	1
Akyürek, Ö	1
Köklü, S	1
Dönmez, M	1
Güneş, F	1
Wang, FY	1
Liu, JM	1
Luo, HH	1
Liu, AH	1
Jiang, Y	2
John, A	1
Al Kaabi, S	1
Doiphode, S	1
Chandra, P	1
Sharma, M	2
Babu, R	1
Yacoub, R	1
Derbala, M	1
Kato, K	2
Tominaga, K	1
Sugimori, S	1
Nagami, Y	1
Kamata, N	1
Yamagami, H	1
Tanigawa, T	1
Shiba, M	1
Watanabe, T	1
Fujiwara, Y	1
Arakawa, T	2
Wang, L	1
Lin, Z	1
Chen, S	2
Li, J	1
Chen, C	1
Huang, Z	1
Ye, B	1
Ding, J	1
Li, W	2
Wu, L	1
Meng, L	1
Du, Q	1
Si, J	1
Körber, A	1
Dissemond, J	1
De Leest, HT	1
Steen, KS	1
Bloemena, E	2
Lems, WF	1
Kuipers, EJ	3
Van de Laar, MA	1
Bijlsma, JW	1
Janssen, M	1
Houben, HH	1
Kostense, PJ	1
Boers, M	1
Dijkmans, BA	1
Bago, J	1
Pevec, B	1
Tomić, M	1
Marusić, M	2
Bakula, V	1
Bago, P	1
Petronilho, F	1
Araújo, JH	2
Steckert, AV	1
Rezin, GT	2
Ferreira, GK	1
Roesler, R	2
Schwartsmann, G	2
Dal-Pizzol, F	2
Streck, EL	2
Esedov, EM	1
Magomedéminova, AS	1
Koosirirat, C	1
Linpisarn, S	1
Changsom, D	1
Chawansuntati, K	1
Wipasa, J	1
van Zanten, SV	1
Desai, S	1
Best, L	1
Cooper-Lesins, G	1
Malatjalian, D	2
Haldane, D	1
Peltekian, K	1
Kohler, JE	1
Blass, AL	1
Liu, J	1
Tai, K	1
Soybel, DI	1
Sood, S	1
Muthuraman, A	1
Gill, NS	1
Bali, M	1
Sharma, PD	1
Zhang, J	1
Ye, LP	1
Shen, LY	1
Petronilho, FC	1
Gonçalves, CL	1
Daufenbach, JF	1
Cardoso, MR	1
Yang, JC	1
Wang, HL	1
Chern, HD	1
Shun, CT	1
Lin, BR	1
Lin, CJ	1
Wang, TH	1
Buonavolontà, R	1
Miele, E	1
Russo, D	1
Vecchione, R	1
Staiano, A	1
Kim, JY	1
Kim, N	1
Park, HK	1
Jo, HJ	1
Shin, CM	1
Lee, SH	1
Park, YS	1
Hwang, JH	1
Kim, JW	1
Jeong, SH	1
Lee, DH	1
Nam, RH	1
Kim, JM	2
Lee, JH	1
Jung, HC	1
Song, IS	1
Tian, XL	1
Zhang, JZ	1
Zhou, LY	1
Geng, QM	1
Han, YJ	1
Seyyedmajidi, M	1
Falaknazi, K	1
Mirsattari, D	1
Zojaji, H	1
Roshani, M	1
Lahmi, F	1
Orimi, PG	1
Hadizadeh, M	1
Zali, M	1
Figura, N	2
Moretti, E	1
Vaglio, L	1
Langone, F	1
Vernillo, R	1
Vindigni, C	1
Giordano, N	1
Kloesel, B	1
Chandan, VS	1
Alexander, GL	1
Prasad, R	1
De Silva, M	1
Koskenpato, J	1
Färkkilä, M	2
Sipponen, P	2
Mak, SK	2
Loo, CK	2
Wong, AM	1
Wong, PN	2
Lo, KY	2
Tong, GM	2
Lam, EK	2
Wong, AK	2
Murakami, K	5
Sato, R	4
Okimoto, T	4
Nasu, M	4
Fujioka, T	5
Kodama, M	4
Kagawa, J	1
Sato, S	2
Abe, H	1
Arita, T	2
Hirayama, F	1
Takagi, S	1
Yokoyama, Y	1
Yamamoto, K	1
Iwao, E	1
Haga, K	1
Cui, M	1
Hu, F	1
Jiang, H	1
Zheng, X	2
Kawano, S	1
Wepner, U	1
Graham, DY	2
Opekun, AR	1
Yamaoka, Y	1
Osato, MS	1
el-Zimaity, HM	2
Miki, I	1
Aoyama, N	3
Sakai, T	1
Shirasaka, D	2
Wambura, CM	1
Maekawa, S	2
Kuroda, K	2
Tamura, T	2
Kita, T	2
Sakaeda, T	1
Okumura, K	2
Kasuga, M	3
Orr, CF	1
Rowe, DB	1
Urakami, Y	1
Sano, T	1
Ozgenc, F	1
Akman, SA	1
Arikan, C	1
Alkanat, MB	1
Aydogdu, S	1
Yagci, RV	1
Muela Molinero, A	1
Ballesteros del Río, B	1
Nistal de Paz, F	1
Fernandez Pérez, E	1
Aguas, M	1
Pons, M	1
Barrera, N	1
Arboix, A	1
Eguileor, B	1
Delás, J	1
Moazzez, R	1
Bartlett, D	1
Anggiansah, A	1
Kaise, M	1
Miwa, J	1
Iihara, K	1
Suzuki, N	1
Oda, Y	1
Ohta, Y	1
Miyamoto, M	2
Haruma, K	5
Yoshihara, M	3
Sumioka, M	2
Kamada, T	2
Masuda, H	1
Nishisaka, T	2
Tanaka, S	2
Chayama, K	2
Hiyama, T	1
Frick, A	1
Kopitz, J	1
Bergemann, N	1
Sapone, A	1
Vaira, D	2
Trespidi, S	1
Perna, F	1
Gatta, L	2
Tampieri, A	1
Ricci, C	2
Cantelli-Forti, G	1
Miglioli, M	3
Biagi, GL	1
Paolini, M	1
Hage, E	1
Hendel, L	1
Gustafsen, J	1
Hendel, J	1
van Zanten, SJ	1
Kolesnikow, T	1
Leung, V	1
O'Rourke, JL	1
Lee, A	1
Santarelli, L	1
Gabrielli, M	1
Candelli, M	1
Cremonini, F	1
Nista, EC	1
Cammarota, G	1
Gasbarrini, G	3
Gasbarrini, A	2
Richter, JE	1
Uthaisaengsook, W	1
Nelis, GF	1
Klinkenberg-Knol, EC	3
Snel, P	2
Goldfain, D	1
Kolkman, JJ	1
Festen, HP	1
Dent, J	2
Zeitoun, P	1
Havu, N	2
Lamm, M	1
Walan, A	3
Ley, C	1
Mohar, A	1
Guarner, J	1
Herrera-Goepfert, R	1
Figueroa, LS	1
Halperin, D	1
Johnstone, I	1
Parsonnet, J	1
Furuta, T	3
Shirai, N	2
Xiao, F	1
El-Omar, EM	1
Rabkin, CS	1
Sugimura, H	1
Ishizaki, T	2
Ohashi, K	2
Gillen, D	2
Wirz, AA	1
McColl, KE	2
Di Mario, F	5
Ingegnoli, A	1
Dal Bò, N	2
Cavestro, GM	1
Moussa, AM	1
Cavallaro, LG	1
Aragona, G	1
Iori, V	1
Pilotto, A	5
Franzè, A	1
Rugge, M	3
Lane, E	1
Lobetti, R	1
Burroughs, R	1
Asaumi, N	1
Niiya, K	1
Yoshida, C	1
Shibakura, M	1
Niiya, M	1
Tanimoto, M	1
Anagnostopoulos, GK	1
Tsiakos, S	1
Margantinis, G	1
Kostopoulos, P	1
Arvanitidis, D	1
Tiesmeier, J	1
Hinner, H	1
Kraus, J	1
Schuppert, F	1
Oderda, G	1
Marinello, D	1
Lerro, P	2
Kuvidi, M	1
de'Angelis, GL	1
Ferzetti, A	1
Cucchiara, S	1
Franco, MT	1
Romano, C	1
Strisciuglio, P	1
Pensabene, L	1
Topaloglu, U	1
Muftuoglu, T	1
Akturk, Z	1
Ekinci, H	1
Peker, O	1
Unalmiser, S	1
Masaoka, T	1
SuzukiKurabayashi, HK	1
Kamiya, AG	1
Ishii, H	3
Kondo, Y	2
Joh, T	2
Sasaki, M	2
Oshima, T	3
Itoh, K	2
Tanida, S	2
Kataoka, H	2
Ohara, H	2
Nomura, T	1
Itoh, M	2
Leung, WK	1
Lin, SR	1
Ching, JY	1
To, KF	1
Ng, EK	1
Chan, FK	1
Lau, JY	1
Sung, JJ	1
Ozturk, Y	1
Buyukgebiz, B	1
Ozer, E	1
Arslan, N	1
Bekem, O	1
Hizli, S	1
Wambura, C	1
Ebara, S	1
Watanabe, Y	1
Calvet, X	1
Montserrat, A	1
Güell, M	1
Vergara, M	1
Gené, E	1
Rollot, F	1
Pajot, O	1
Chauvelot-Moachon, L	1
Nazal, EM	1
Kélaïdi, C	1
Blanche, P	1
Farinati, F	1
Cardin, R	1
Russo, VM	1
Busatto, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047]	Phase 2/Phase 3	138 participants	Interventional	2006-01-31	Recruiting
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543]	Phase 4	133 participants (Actual)	Interventional	2012-09-10	Completed
the Effect of Daily Use of Proton Pump Inhibitors for One Month on Renal Function[NCT03910647]	Phase 2	200 participants (Anticipated)	Interventional	2019-12-31	Not yet recruiting
Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05802888]	Phase 4	260 participants (Anticipated)	Interventional	2023-03-12	Recruiting
Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.[NCT05431075]	Phase 4	407 participants (Anticipated)	Interventional	2022-07-31	Not yet recruiting
Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05432115]	Phase 4	407 participants (Anticipated)	Interventional	2022-06-25	Recruiting
European Registry on the Management of Helicobacter Pylori Infection[NCT02328131]		10,000 participants (Anticipated)	Observational	2013-06-30	Recruiting
Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084]	Phase 3	296 participants	Interventional	2003-04-30	Recruiting
Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441]	Phase 4	338 participants (Actual)	Interventional	2010-12-31	Completed
Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection[NCT00656968]	Phase 4	232 participants (Actual)	Interventional	2007-05-31	Completed
Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534]	Phase 3	407 participants (Actual)	Interventional	2006-10-31	Completed
Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study)[NCT00154440]	Phase 3	200 participants	Interventional	2001-11-30	Recruiting
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757]		48 participants (Anticipated)	Interventional	2012-03-31	Not yet recruiting
Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection[NCT04652284]	Phase 3	300 participants (Anticipated)	Interventional	2021-05-01	Not yet recruiting
Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432]	Phase 2	90 participants (Anticipated)	Interventional	2023-07-15	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT00656968)
Timeframe: one month after finishing study drugs

Number of Participants Who Had Good Drug Compliance

Intervention	participants (Number)
Concomitant Therapy (A)	92
Sequential Therapy (B)	95

Good drug compliance is defined as taking equal to or more than 80% of eradication medicines (NCT00656968)
Timeframe: one month after finishing test therapy

Article	Year
The clinical efficacy and safety of atropine combined with omeprazole in the treatment of patients with acute gastritis: a systematic review and meta-analysis. Annals of palliative medicine, 2021, Volume: 10, Issue:9 Topics: Atropine; Gastritis; Humans; Omeprazole; Treatment Outcome	2021
Gastric MALT lymphoma and Helicobacter pylori. Medicina clinica, 2019, 01-18, Volume: 152, Issue:2 Topics: Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Ther	2019
[Helicobacter pylori induced gastritis: recent topics on eradication therapy]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2002, Volume: 99, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati	2002
Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease. The American journal of medicine, 2003, Aug-18, Volume: 115 Suppl 3A Topics: Age Factors; Barrett Esophagus; Female; Gastric Acid; Gastritis; Gastroesophageal Reflux; Gastrointe	2003
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2003, Volume: 100, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes	2003
[Eradication of Helicobacter pylori]. Krankenpflege Journal, 2005, Volume: 43, Issue:4-6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy,	2005
[Proton pump inhibitors in developmental period medicine]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:128 Topics: Adult; Age Factors; Anti-Ulcer Agents; Child; Drug Interactions; Duodenitis; Enzyme Inhibitors; Esom	2007
[Functional dyspepsia: approaches to Helicobacter pylori eradication therapy]. Leber, Magen, Darm, 1995, Volume: 25, Issue:3 Topics: Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Gastritis	1995
[How to use proton pump inhibitors and histamine H2 antagonists in the therapy of peptic ulcer]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995, Jun-10, Volume: 84, Issue:6 Topics: Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazol	1995
Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis. Bailliere's clinical gastroenterology, 1993, Volume: 7, Issue:1 Topics: Animals; Carcinoid Tumor; Enterochromaffin Cells; Gastric Acid; Gastric Mucosa; Gastrins; Gastritis;	1993
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. Clinical therapeutics, 1993, Volume: 15 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag	1993
Omeprazole, Helicobacter pylori, and gastritis. Journal of gastroenterology, 1994, Volume: 29 Suppl 7 Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicoba	1994
[Omeprazole treatment and fever]. Medicina clinica, 1994, Sep-24, Volume: 103, Issue:9 Topics: Aged; Aged, 80 and over; Fever; Gastritis; Hernia, Hiatal; Humans; Male; Omeprazole	1994
The role of acid inhibition in the treatment of Helicobacter pylori infection. Scandinavian journal of gastroenterology. Supplement, 1994, Volume: 201 Topics: Amoxicillin; Depression, Chemical; Drug Administration Schedule; Drug Therapy, Combination; Gastric	1994
The role of Helicobacter pylori in peptic ulcer disease. Scandinavian journal of gastroenterology. Supplement, 1994, Volume: 201 Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helic	1994
Emerging strategies for managing peptic ulcer disease. Scandinavian journal of gastroenterology. Supplement, 1994, Volume: 201 Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Depression, Chemical; Drug Therapy, Combinatio	1994
[Current therapy of Helicobacter pylori infection]. Leber, Magen, Darm, 1994, Volume: 24, Issue:1 Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infe	1994
[Diagnosis and treatment of Helicobacter pylori]. Nihon Ika Daigaku zasshi, 1997, Volume: 64, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Dr	1997
Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter, 1996, Volume: 1, Issue:1 Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Micro	1996
Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors? Italian journal of gastroenterology and hepatology, 1997, Volume: 29, Issue:6 Topics: Anti-Ulcer Agents; Atrophy; Gastric Acid; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Helico	1997
[Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?]. Gastroenterologia y hepatologia, 1998, Volume: 21 Suppl 1 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials a	1998
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. Journal of clinical gastroenterology, 1998, Volume: 27 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C	1998
[Indications and use of omeprazole in esophago-gastro-duodenal diseases]. Revista clinica espanola, 1999, Volume: 199, Issue:11 Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis;	1999
Microbial ecology and treatment of Helicobacter pylori infections: review. Journal of chemotherapy (Florence, Italy), 2000, Volume: 12, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin;	2000
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient. Haematologica, 2002, Volume: 87, Issue:1 Topics: Acute Disease; Amikacin; Anemia, Aplastic; Antilymphocyte Serum; Combined Modality Therapy; Cyclospo	2002
[Helicobacter heilmannii-associated gastritis]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combina	2002

Article	Year
Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PloS one, 2017, Volume: 12, Issue:4 Topics: Adult; Amoxicillin; Carnosine; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicob	2017
Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance. Acta gastro-enterologica Belgica, 2013, Volume: 76, Issue:1 Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Female; Gastritis; Heli	2013
Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2013, Volume: 24, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clarithromycin; Drug The	2013
Ten-day bismuth-containing quadruple therapy is effective as first-line therapy for Helicobacter pylori-related chronic gastritis: a prospective randomized study in China. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2017, Volume: 23, Issue:6 Topics: Adult; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobact	2017
Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. Journal of clinical gastroenterology, 2009, Volume: 43, Issue:2 Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents	2009
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:1-2 Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Sc	2009
Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. International immunopharmacology, 2010, Volume: 10, Issue:7 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Load;	2010
Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy, 2011, Volume: 31, Issue:3 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; C	2011
Helicobacter pylori chronic gastritis in children: to eradicate or not to eradicate? The Journal of pediatrics, 2011, Volume: 159, Issue:1 Topics: Adolescent; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Child; C	2011
Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2011, Volume: 12, Issue:3 Topics: Amoxicillin; Anti-Bacterial Agents; Antibodies, Bacterial; Ciprofloxacin; Creatinine; Dose-Response	2011
Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia. Scandinavian journal of gastroenterology, 2002, Volume: 37, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Chronic Disease; Drug T	2002
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	2002
[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. Zhonghua yi xue za zhi, 2002, Sep-25, Volume: 82, Issue:18 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti	2002
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	2003
Helicobacter pylori stimulates inducible nitric oxide synthase in diverse topographical patterns in various gastroduodenal disorders. Digestive diseases and sciences, 2003, Volume: 48, Issue:4 Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; E	2003
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Benzi	2003
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut, 2004, Volume: 53, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disease Progression; Double-	2004
Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2004, Volume: 13, Issue:1 Topics: Adenocarcinoma; Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Gastritis; Helicobacter Infec	2004
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A	2004
Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study. Journal of clinical gastroenterology, 2004, Volume: 38, Issue:6 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Female; Follow-Up Stud	2004
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial. Helicobacter, 2004, Volume: 9, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind	2004
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. Alimentary pharmacology & therapeutics, 2004, Volume: 20 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis;	2004
Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut, 2004, Volume: 53, Issue:9 Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Disease Progression; Drug Therapy, Combination	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu	2004
Differential effects of Helicobacter pylori eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2004, Volume: 13, Issue:11 Pt 1 Topics: Anti-Ulcer Agents; DNA Adducts; DNA Damage; Esophageal Diseases; Esophagogastric Junction; Female; G	2004
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent	2005
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery. Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu	2005
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients. World journal of gastroenterology, 2005, Apr-21, Volume: 11, Issue:15 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles;	2005
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis	2005
Effect of high-dose aspirin on Helicobacter pylori eradication. Digestive diseases and sciences, 2005, Volume: 50, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Chronic Disease; Clarithromyc	2005
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology, 2005, Volume: 129, Issue:5 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal	2005
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology, 2005, Volume: 129, Issue:5 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal	2005
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology, 2005, Volume: 129, Issue:5 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal	2005
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology, 2005, Volume: 129, Issue:5 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal	2005
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. Digestive diseases and sciences, 2006, Volume: 51, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents	2006
Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut, 2006, Volume: 55, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cadherins; Chronic Disease; Clarithromycin; D	2006
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. Alimentary pharmacology & therapeutics, 2006, Feb-15, Volume: 23, Issue:4 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co	2006
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:1 Pt 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz	2006
[Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis]. Likars'ka sprava, 2005, Issue:8 Topics: Adult; Aged; alpha-Tocopherol; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antioxidants;	2005
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology, 2006, Volume: 52, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents	2006
Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. The New England journal of medicine, 2006, Apr-27, Volume: 354, Issue:17 Topics: Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Gastric Acid; Gastritis; Goiter; Helicobacter Infec	2006
Furazolidone-based triple therapy for H pylori gastritis in children. World journal of gastroenterology, 2006, Sep-14, Volume: 12, Issue:34 Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Child; Child, Preschool	2006
Improvement of the eradication rate of Helicobacter pylori gastritis in children is by adjunction of omeprazole to a dual antibiotherapy. Acta paediatrica (Oslo, Norway : 1992), 2007, Volume: 96, Issue:1 Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc	2007
[Age and eradication treatment of duodenal ulcer]. Terapevticheskii arkhiv, 2007, Volume: 79, Issue:2 Topics: Adolescent; Adult; Age Factors; Aged; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Combinations;	2007
Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. World journal of gastroenterology, 2007, Sep-14, Volume: 13, Issue:34 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin;	2007
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. Journal of clinical gastroenterology, 2008, Volume: 42, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co	2008
Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? World journal of gastroenterology, 2008, May-14, Volume: 14, Issue:18 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Dose-Response	2008
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study. Zeitschrift fur Gastroenterologie, 1995, Volume: 33, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female;	1995
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. The American journal of gastroenterology, 1995, Volume: 90, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B	1995
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. Leber, Magen, Darm, 1995, Volume: 25, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid	1995
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. Digestive diseases and sciences, 1995, Volume: 40, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Clarithromyc	1995
Two-year follow-up of duodenal ulcer patients treated with omeprazole and amoxicillin. Digestion, 1995, Volume: 56, Issue:3 Topics: Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow	1995
Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. The American journal of gastroenterology, 1995, Volume: 90, Issue:9 Topics: Adult; Amoxicillin; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric	1995
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? The American journal of gastroenterology, 1995, Volume: 90, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinatio	1995
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. The American journal of gastroenterology, 1995, Volume: 90, Issue:5 Topics: Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Hel	1995
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. European journal of gastroenterology & hepatology, 1994, Volume: 6 Suppl 1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com	1994
Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication. Scandinavian journal of gastroenterology, 1994, Volume: 29, Issue:10 Topics: Adult; Age Factors; Amoxicillin; Chronic Disease; Drug Therapy, Combination; Dyspepsia; Female; Gast	1994
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection]. Deutsche medizinische Wochenschrift (1946), 1995, Mar-17, Volume: 120, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom	1995
High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. Digestion, 1995, Volume: 56, Issue:1 Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer	1995
Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori. The American journal of gastroenterology, 1994, Volume: 89, Issue:10 Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies;	1994
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1994, Volume: 8, Issue:4 Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Female; Gastritis; Helicobacter	1994
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scandinavian journal of gastroenterology. Supplement, 1994, Volume: 201 Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastrit	1994
Lansoprazole and Helicobacter pylori infection. Clinical therapeutics, 1993, Volume: 15 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method;	1993
Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology, 1996, Volume: 110, Issue:2 Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Du	1996
Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology, 1996, Volume: 110, Issue:3 Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastric Acidity Determination;	1996
Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. The American journal of gastroenterology, 1996, Volume: 91, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com	1996
Effects of permanent eradication or transient clearance of Helicobacter pylori on histology of gastric mucosa using omeprazole with or without antibiotics. Scandinavian journal of gastroenterology. Supplement, 1996, Volume: 215 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Co	1996
Helicobacter pylori eradication--evaluation of triple therapy containing omeprazole. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 1996, Volume: 15, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul	1996
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagit	1996
Effect of omeprazole on Helicobacter pylori urease activity in vivo. European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:8 Topics: Adult; Aged; Enzyme Inhibitors; Female; Gastritis; Helicobacter pylori; Humans; Male; Middle Aged; O	1996
Significant increase in eradication rates of Helicobacter pylori infection with two consecutive dual therapies (omeprazole and amoxycillin or omeprazole and clarithromycin). A randomized study in 450 Spanish patients. Journal of gastroenterology, 1996, Volume: 31 Suppl 9 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Dr	1996
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:6 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Admin	1996
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer	1996
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. European journal of gastroenterology & hepatology, 1997, Volume: 9, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A	1997
Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Cross-Over Studies; Diagnosis, Diffe	1997
An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastriti	1997
Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. Pediatrics, 1997, Volume: 100, Issue:1 Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Biopsy; Child; C	1997
Another therapeutic schedule in eradication of Helicobacter pylori. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, 1997, Volume: 51, Issue:2 Topics: Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti	1997
Doubling the omeprazole dose (40 mg b.d. vs. 20 mg b.d.) in dual therapy with amoxycillin increases the cure rate of Helicobacter pylori infection in duodenal ulcer patients. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:3 Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Fema	1997
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis. International journal of clinical practice, 1997, Volume: 51, Issue:4 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination;	1997
Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:4 Topics: Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastritis; Helicobacter I	1997
Parietal cell protrusions in gastric ulcer disease. Human pathology, 1997, Volume: 28, Issue:10 Topics: Chronic Disease; Double-Blind Method; Endoscopy, Digestive System; Gastric Mucosa; Gastritis; Helico	1997
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter, 1996, Volume: 1, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar	1996
Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. Helicobacter, 1996, Volume: 1, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug The	1996
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter, 1996, Volume: 1, Issue:3 Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; D	1996
Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. The American journal of gastroenterology, 1998, Volume: 93, Issue:1 Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Chronic Disease; C	1998
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut, 1997, Volume: 41, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age	1997
Dual therapy with high or low doses of omeprazole does not achieve an acceptable rate of Helicobacter pylori eradication in duodenal ulcer patients. A multicentre randomized long-term detailed study. Italian journal of gastroenterology and hepatology, 1997, Volume: 29, Issue:6 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Dose-Response Relationship	1997
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double	1998
[Omeprazole, clarithromycin and amoxicillin therapy for Helicobacter pylori infection]. Zhonghua nei ke za zhi, 1996, Volume: 35, Issue:12 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Drug	1996
Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study. Scandinavian journal of gastroenterology, 1998, Volume: 33, Issue:5 Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsi	1998
One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. Pediatrics, 1998, Volume: 102, Issue:1 Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Administrat	1998
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti	1998
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gas	1998
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. Helicobacter, 1998, Volume: 3, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti	1998
The value of different detection methods of Helicobacter pylori during treatment. Journal of clinical gastroenterology, 1998, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bacteriological Techniques; Biopsy; Drug Administration	1998
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. The American journal of gastroenterology, 1998, Volume: 93, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy	1998
Dual versus triple therapy: comparison of five antibiotic regimens for eradication of Helicobacter pylori in a prospective, randomized study. Zeitschrift fur Gastroenterologie, 1998, Volume: 36, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response	1998
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. Helicobacter, 1998, Volume: 3, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	1998
Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. Acta paediatrica (Oslo, Norway : 1992), 1999, Volume: 88, Issue:2 Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithr	1999
Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. Journal of gastroenterology and hepatology, 1999, Volume: 14, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Female; Ga	1999
Helicobacter pylori as a possible bacterial focus of chronic urticaria. Dermatology (Basel, Switzerland), 1999, Volume: 198, Issue:2 Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Female; Gastritis	1999
Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion, 1999, Volume: 60, Issue:3 Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Bacterial Adhesion; Breath Tests; Colony Count, Micr	1999
Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. Digestion, 1999, Volume: 60, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Cla	1999
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. Journal of gastroenterology and hepatology, 1999, Volume: 14, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial	1999
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association. Italian journal of gastroenterology and hepatology, 1999, Volume: 31, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Do	1999
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. Journal of clinical gastroenterology, 1999, Volume: 29, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; C	1999
[Is lack of stomach carcinoma prevention by Helicobacter pylori eradication unethical?]. Zeitschrift fur Gastroenterologie, 1999, Volume: 37, Issue:7 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Et	1999
Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter, 1999, Volume: 4, Issue:3 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat	1999
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scandinavian journal of gastroenterology, 1999, Volume: 34, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial	1999
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. The New England journal of medicine, 1999, Oct-07, Volume: 341, Issue:15 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Cla	1999
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. The American journal of physiology, 1999, Volume: 277, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	1999
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. Journal of gastroenterology, 1999, Volume: 34 Suppl 11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	1999
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz	2000
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. Helicobacter, 2000, Volume: 5, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul	2000
Garlic oil and Helicobacter pylori infection. The American journal of gastroenterology, 2000, Volume: 95, Issue:2 Topics: Adult; Allyl Compounds; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Disulfides; Dyspe	2000
Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis. Journal of pediatric gastroenterology and nutrition, 2000, Volume: 30, Issue:2 Topics: Abdominal Pain; Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool	2000
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection. Journal of pediatric gastroenterology and nutrition, 2000, Volume: 30, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biop	2000
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:3 Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose-	2000
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer]. Medicinski arhiv, 2000, Volume: 54, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	2000
Five-day triple therapy in Helicobacter pylori-positive duodenal ulcer: an eighteen-month follow-up. Journal of clinical gastroenterology, 2000, Volume: 31, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	2000
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:10 Topics: Anti-Ulcer Agents; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Gastritis; Gastroscopy; Helicobact	2000
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. The American journal of gastroenterology, 2000, Volume: 95, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles	2000
Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter, 2000, Volume: 5, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, C	2000
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter, 2000, Volume: 5, Issue:4 Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Dr	2000
A short-term eradication therapy for Helicobacter pylori acute gastritis. Journal of gastroenterology and hepatology, 2000, Volume: 15, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Ant	2000
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. The American journal of gastroenterology, 2001, Volume: 96, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz	2001
Comparison of two regimens on eradication of Helicobacter pylori. The Journal of the Association of Physicians of India, 2000, Volume: 48, Issue:8 Topics: Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th	2000
Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. The American journal of gastroenterology, 2001, Volume: 96, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles;	2001
Helicobacter pylori and iron deficiency anaemia in children. Scandinavian journal of gastroenterology, 2001, Volume: 36, Issue:7 Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath T	2001
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib	2001
Omeprazole combined with amoxicillin and clarithromycin in the eradication of Helicobacter pylori in children with gastritis: A prospective randomized double-blind trial. The Journal of pediatrics, 2001, Volume: 139, Issue:5 Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Double-Blind Method;	2001
Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL). Annals of hematology, 2001, Volume: 80 Suppl 3 Topics: Aged; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Gastr	2001
Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimid	2001
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Archives of internal medicine, 2002, Jan-28, Volume: 162, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	2002
Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin. Acta medica (Hradec Kralove), 2001, Volume: 44, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	2001
Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World journal of gastroenterology, 2001, Volume: 7, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Gastrointe	2001
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy;	2002
Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. European journal of gastroenterology & hepatology, 2002, Volume: 14, Issue:3 Topics: Adult; Aged; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin	2002
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter, 2002, Volume: 7, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents	2002
[Comparison of the efficacy of omeprazole/bismuth subcitrate or triple therapy in Helicobacter pylori gastritis. A prospective controlled study]. Schweizerische medizinische Wochenschrift, 1992, Sep-26, Volume: 122, Issue:39 Topics: Antacids; Breath Tests; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helic	1992
Two weeks treatment with amoxicillin/omeprazole for eradication of Helicobacter pylori. Zeitschrift fur Gastroenterologie, 1992, Volume: 30, Issue:11 Topics: Amoxicillin; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, C	1992
[Short-term therapy with high dosage omeprazole and amoxicillin for Helicobacter pylori eradication. A pilot study]. Medizinische Klinik (Munich, Germany : 1983), 1992, Mar-15, Volume: 87, Issue:3 Topics: Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combinati	1992
The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. Zeitschrift fur Gastroenterologie, 1991, Volume: 29, Issue:11 Topics: Adult; Aged; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; F	1991
Enhanced clearing of Helicobacter pylori after omeprazole plus roxithromycin treatment. FEMS microbiology letters, 1991, Dec-01, Volume: 68, Issue:3 Topics: Drug Combinations; Duodenal Ulcer; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans;	1991
Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Digestive diseases and sciences, 1991, Volume: 36, Issue:5 Topics: Adult; Chronic Disease; Double-Blind Method; Duodenal Ulcer; Female; Gastritis; Helicobacter Infecti	1991
Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 167 Topics: Adult; Amoxicillin; Campylobacter Infections; Double-Blind Method; Drug Therapy, Combination; Female	1989

omeprazole and Gastritis